How Leqembi Helps with Early and What to Expect

Leqembi (lecanemab) is a monoclonal antibody drug that has shown promise in slowing the progression of early-stage Alzheimer's disease. It works by binding to and neutralizing a toxic form of the beta-amyloid protein, which is believed to play a key role in the development of Alzheimer's.

How Leqembi Helps with Early Alzheimer's

In clinical trials, Leqembi has been shown to reduce the levels of beta-amyloid plaques in the brain and to slow the decline in cognitive function in people with early Alzheimer's disease. The drug has also been shown to be safe and well-tolerated.

The benefits of Leqembi are most pronounced in people who are in the early stages of Alzheimer's disease, when the symptoms are mild and the disease process has not yet caused significant damage to the brain. The drug is not effective in people with advanced Alzheimer's disease.

What to Expect from Leqembi Treatment

If you are considering taking Leqembi for early Alzheimer's disease, it is important to talk to your doctor about what to expect from treatment. The drug is given by intravenous infusion, and you will need to receive infusions every two weeks. Treatment with Leqembi may continue for several years.

The side effects of Leqembi are generally mild and include:

* Headache

* Nausea

* Fatigue

* Infusion-related reactions

Some people may also experience more serious side effects, such as bleeding in the brain or swelling in the brain. Your doctor will monitor you for side effects and will adjust your dose if necessary.

Outlook for People Taking Leqembi

The outlook for people taking Leqembi for early Alzheimer's disease is still uncertain. The drug has shown promise in clinical trials, but it is not known for sure how effective it will be in the long term. However, Leqembi represents an important step forward in the treatment of Alzheimer's disease and offers hope to people who are living with this condition.